Medeor Therapeutics is a biotechnology company that dedicates to dedicates to the development of personalized cellular immunotherapies.
Medeor Therapeutics is a developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's cellular immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 22, 2018 | Grant | $18.80M | 1 | California Institute for Regenerative Medicine | — | Detail |
Nov 27, 2017 | Series B | $57M | 5 | RA Capital Management | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
California Institute for Regenerative Medicine | Yes | Grant |
RA Capital Management | Yes | Series B |
6 Dimensions Capital | — | Series B |
Sofinnova Investments | — | Series B |
Vivo Capital | — | Series B |
WuXi Healthcare Ventures | — | Series B |